Dr Lal PathLabs Approves Rs 168 Crore Acquisition Of 70pct SN Genelab Stake

Board approved 70% stake buy in SN Genelab, Gujarat genomics diagnostics, for up to 168 Cr cash plus 31.5 Cr earnout; FY26 turnover 58 Cr; close by Nov 30 2026. First genomics scale entry and largest in recent bolt-on sequence; diagnostics-adjacent but step change in size versus small-deal history, cash-funded from net-cash position. Adds genomics capability as 70% subsidiary; earnout links price to performance. Target profitability, integration and scale-up plans not disclosed.